1653 – Amendment to eligibility criteria for tisagenlecleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma - removal of the requirement for patients to be “CD19-positive”

Page last updated: 15 February 2021

Application Detail

Description of Medical Service

Tisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Diffuse Large B-Cell Lymphoma is an aggressive and common subtype of Non-Hodgkin Lymphoma.

Reason for Application

Request to amend the eligibility criteria to remove the requirement for patients to be “CD19-positive”.

Medical Service Type

Hybrid health technology

Previous Application Number/s


Associated Documentation

Public Summary Document

Public Summary Document (PDF 318 KB)
Public Summary Document (Word 73 KB)

Meetings for this Application


Expedited Bypassing PASC


Expedited Bypassing ESC


26-27 November 2020